Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS

Neurology

Volumn 46, Issue 5, 1996, Pages 1442-1444

  McGuire, D ^a,b,h   Garrison, L ^b   Armon, C ^b   Barohn, R ^c   Bryan, W ^c   Miller, R ^d   Parry, G ^e   Petajan, J ^f   Ross, M ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; DAILY LIFE ACTIVITY; DISABILITY; FEMALE; HEALTH STATUS; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MUSCLE STRENGTH; NEUROMUSCULAR FUNCTION; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0030014596     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.46.5.1442     Document Type: Article

References (9)

1. Andres LA, Hedlund W, Finison L, Conlon T, Felmus M, Munsat TL. Quantitative motor assessment in amyotrophic lateral sclerosis. Neurology 1986;36:937-941.
2. Miller RG, Armon C, Barohn R, et al. A controlled trial of recombinant human ciliary neurotrophic factor (rhCNTF) in amyotrophic lateral sclerosis [abstract]. Neurology 1995; 45(suppl 4):A281.
3. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981;19:787-805.
4. Zeldow PB, Pavlou M. Physical and psychosocial functioning in multiple sclerosis: descriptions, correlations, and a tentative typology. Br J Med Psychol 1988;61(pt 2):185-195.
5. Sano M, Stern Y, Marder K, Mayeux R. A controlled trial of piracetam in intellectually impaired patients with Parkinson's disease. Mov Disord 1990;5:230-234.
6. Ross MA, Parry GJ, Miller RG, et al. Evaluation of amyotrophic lateral sclerosis diagnostic criteria (ALSDC) for a controlled trial of recombinant human ciliary neurotrophic factor [abstract]. Neurology 1995;45(suppl 4):A280.
7. Andres PL, Finison LJ, Conlon T, Thibodeau LM, Munsat TL. Use of composite scores (megascores) to measure deficit in amyotrophic lateral sclerosis. Neurology 1988;38:405-408.
8. Pradas J, Finison L, Andres PL, Thornell B, Hollander D, Munsat TL. The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials. Neurology 1993;43:751-755.
9. Longstreth WT, Nelson L, Linde M, Munoz D. Utility of the sickness impact profile in Parkinson's disease. J Geriatr Psychiatry Neurol 1992;5:142-148.